Talem Enters into Collaboration and License Option Agreement with Astellas
30 Mar 2023 //
BUSINESSWIRE
Talem Announces a AI-Driven Antibody Discovery Collaboration with Libera Bio
15 Mar 2023 //
BUSINESSWIRE
Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
12 Oct 2022 //
BUSINESSWIRE
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity
14 Sep 2022 //
BUSINESSWIRE